ArticleTranslational oncology2026
Precision management of radiotherapy interruption in locoregionally advanced nasopharyngeal carcinoma: Induction chemotherapy counteracts the survival impact in high-risk patients defined by a novel model.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop a risk stratification model to identify high-risk locoregionally advanced nasopharyngeal carcinoma (NPC) susceptible to radiotherapy interruption (RTI) ≥5 days and evaluate whether induction chemotherapy (IC) mitigated the associated survival detriment.
methodsWe retrospectively analyzed 820 patients treated with intensity-modulated radiotherapy, randomly allocated into training (n = 490) and validation (n = 330) cohorts. Prognostic factors for overall survival (OS) were screened using univariate and multivariate analyses. A Cox regression-based prognostic model was developed and evaluated via C-index and calibration plots. RTI ≥5 days impact on survival endpoints-OS, locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and failure-free survival (FFS)-was assessed across risk groups, with IC effect analyzed in high-risk patients using propensity score matching.
resultsA prognostic model incorporating age, T stage, N stage, and EBV-DNA >4000 copies/mL was established. The prognostic index (PI) stratified patients into high- and low-risk groups, with high-risk patients exhibiting significantly inferior survival in OS, DMFS, and FFS (all P < 0.05). The model demonstrated C-indices of 0.744 (training) and 0.658 (validation) for OS prediction, outperforming the 8th AJCC staging system. RTI ≥5 days significantly reduced OS in high-risk patients (training: HR 1.816, P = 0.034; validation: HR 2.310, P = 0.024) but not in low-risk patients. Importantly, IC ≥2 cycles eliminated RTI-associated survival differences in high-risk patients following confounding adjustment.
conclusionThe developed model effectively identified high-risk NPC patients vulnerable to RTI ≥5 days, with IC shown to mitigate this risk. These findings support the implementation of risk-stratified treatment strategies and proactive IC use to counter unavoidable treatment delays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.